Comparative Pharmacology
Head-to-head clinical analysis: ADAPALENE versus CLARAVIS.
Head-to-head clinical analysis: ADAPALENE versus CLARAVIS.
ADAPALENE vs CLARAVIS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Retinoic acid receptor agonist; binds to RARβ/γ nuclear receptors, modulating gene expression to normalize follicular keratinization and reduce comedogenesis.
Isotretinoin, a retinoid, reduces sebum production, inhibits sebaceous gland activity, and normalizes follicular keratinization. It also exhibits anti-inflammatory effects.
Apply a pea-sized amount topically to affected areas once daily in the evening.
Oral: 30 mg once daily after a meal for 12 weeks; administration with high-fat meal increases absorption.
None Documented
None Documented
The terminal elimination half-life of adapalene after topical application is approximately 17 hours (range 7–51 hours), reflecting slow release from skin depot and hepatic clearance. This supports once-daily dosing.
Clinical Note
moderateAdapalene + Gatifloxacin
"Adapalene may increase the neuroexcitatory activities of Gatifloxacin."
Clinical Note
moderateAdapalene + Rosoxacin
"Adapalene may increase the neuroexcitatory activities of Rosoxacin."
Clinical Note
moderateAdapalene + Levofloxacin
"Adapalene may increase the neuroexcitatory activities of Levofloxacin."
Clinical Note
moderateAdapalene + Trovafloxacin
"Adapalene may increase the neuroexcitatory activities of Trovafloxacin."
Terminal half-life: 19-24 hours in adults; prolonged in renal impairment (up to 50 hours in ESRD).
Adapalene is eliminated primarily via biliary excretion into feces. After oral administration in animals, approximately 80% of the dose is recovered in feces and about 10% in urine; for topical application, systemic absorption is minimal and the small absorbed fraction undergoes similar hepatobiliary elimination.
Renal: 90% as unchanged drug; fecal: 5%; biliary: <1%.
Category D/X
Category C
Retinoid
Retinoid